Annovis Bio Past Earnings Performance
Past criteria checks 0/6
Annovis Bio's earnings have been declining at an average annual rate of -56.1%, while the Biotechs industry saw earnings growing at 19.7% annually.
Key information
-56.1%
Earnings growth rate
-23.5%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Annovis Bio Rallies On Missed ITT Parkinson's Study Endpoints
Jul 08Annovis: Strong Sell Reiteration Prior To Phase 3 Data In Parkinson's Disease
Jun 30Annovis Bio: Alzheimer's Phase 2/3 Topline Readout Puts Future For Buntanetap Into Question
May 02Annovis: Potentially Encouraging Anecdotes, Weighing Phase 3 Parkinson's Prospects
Feb 12Annovis And Alzheimer's Disease: The Best-Laid Plans
Jan 30Annovis Bio: Buntanetap Likely To Disappoint In The Upcoming AD And PD Clinical Trials
Jan 20Annovis: Due Diligence Prior To Parkinson's And Alzheimer's Readouts
Oct 16Annovis Bio (NYSE:ANVS) Will Have To Spend Its Cash Wisely
Sep 08
Annovis Bio: End Of 2023 Parkinson's Data Could Shift Momentum
Jun 28Annovis wins EU nod to expand late-stage trial for Parkinson's candidate
Feb 08We Think Annovis Bio (NYSE:ANVS) Can Afford To Drive Business Growth
Jan 28Annovis gains amid ‘strong’ enrollment in late-stage trial Parkinson's drug
Jan 25Annovis: Late-Stage Parkinson's Disease Trial Advancement Makes It Worth A Look
Oct 06We're Hopeful That Annovis Bio (NYSE:ANVS) Will Use Its Cash Wisely
Sep 15Annovis Bio announces publication of three U.S. patents covering lead asset
Sep 13Annovis Bio gains as dosing begins in late-stage trial for Parkinson’s candidate
Aug 24Annovis Bio wins FDA nod to begin late-stage study for Parkinson's candidate
Jul 07Annovis Bio (NYSE:ANVS) Is In A Good Position To Deliver On Growth Plans
May 14We Think Annovis Bio (NYSE:ANVS) Can Afford To Drive Business Growth
Feb 10Here's Why We're Not Too Worried About Annovis Bio's (NYSEMKT:ANVS) Cash Burn Situation
Apr 16Do Institutions Own Annovis Bio, Inc. (NYSEMKT:ANVS) Shares?
Feb 23We Think Annovis Bio (NYSEMKT:ANVS) Can Afford To Drive Business Growth
Jan 01
Revenue & Expenses Breakdown
How Annovis Bio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -43 | 6 | 35 |
| 31 Mar 24 | 0 | -48 | 5 | 38 |
| 31 Dec 23 | 0 | -56 | 6 | 39 |
| 30 Sep 23 | 0 | -42 | 6 | 36 |
| 30 Jun 23 | 0 | -33 | 8 | 26 |
| 31 Mar 23 | 0 | -30 | 8 | 22 |
| 31 Dec 22 | 0 | -25 | 9 | 17 |
| 30 Sep 22 | 0 | -24 | 10 | 13 |
| 30 Jun 22 | 0 | -20 | 10 | 10 |
| 31 Mar 22 | 0 | -17 | 8 | 8 |
| 31 Dec 21 | 0 | -14 | 6 | 8 |
| 30 Sep 21 | 0 | -10 | 4 | 7 |
| 30 Jun 21 | 0 | -8 | 3 | 6 |
| 31 Mar 21 | 0 | -8 | 4 | 5 |
| 31 Dec 20 | 0 | -5 | 4 | 3 |
| 30 Sep 20 | 0 | -4 | 3 | 2 |
| 30 Jun 20 | 0 | -3 | 3 | 2 |
| 31 Mar 20 | 0 | -1 | 1 | 1 |
| 31 Dec 19 | 0 | -1 | 1 | 1 |
| 30 Sep 19 | 0 | -1 | 1 | 0 |
| 30 Jun 19 | 0 | -1 | 1 | 0 |
| 31 Mar 19 | 0 | -1 | 1 | 0 |
| 31 Dec 18 | 0 | -1 | 1 | 0 |
Quality Earnings: ANVS is currently unprofitable.
Growing Profit Margin: ANVS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ANVS is unprofitable, and losses have increased over the past 5 years at a rate of 56.1% per year.
Accelerating Growth: Unable to compare ANVS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ANVS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).
Return on Equity
High ROE: ANVS's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.